 5MG.webp)
GLP 1 (S)
🚚 Ships same day if ordered before 2PM EST
Semaglutide-class GLP-1 receptor agonist. Studied extensively for metabolic research, glycemic regulation, and body composition applications.
View Certificate of Analysis →Compound Profile
Pharmaceutical Data Sheet
Mechanism of Action
How GLP 1 (S) Works
GLP-1 (S) / Semaglutide class compounds are highly potent, long-acting GLP-1 receptor agonists. GLP-1 receptors are expressed in pancreatic beta cells (insulin secretion), hypothalamic satiety centers (appetite suppression), gastric smooth muscle (motility), and cardiac tissue. Semaglutide's fatty acid chain enables albumin binding, extending half-life to ~7 days.
- Beta cell: glucose-dependent insulin secretion
- Hypothalamus: NPY/AgRP suppression for satiety
- Gastric: slows gastric emptying
- Heart: cardioprotective direct and indirect effects
- Increases insulin secretion dose-dependently
- Reduces glucagon secretion postprandially
- Protects and promotes beta-cell proliferation
- Reduces HbA1c by 1.4–1.8% in T2D trials
- Activates hypothalamic POMC/CART neurons
- Reduces NPY/AgRP orexigenic signaling
- Increases satiety signaling from nucleus tractus solitarius
- Reduces food reward via mesolimbic dopamine modulation
GLP-1R activation triggers Gs-coupled adenylyl cyclase, elevating cAMP in beta cells — driving insulin secretion in a glucose-dependent manner. In the hypothalamus, GLP-1R activation reduces neuropeptide Y (NPY) and agouti-related peptide (AgRP) expression, suppressing appetite. Vagal afferent signaling from gut GLP-1Rs further reduces food intake.
Drucker DJ, Cell Metab (2018): Mechanisms of action and therapeutic application of GLP-1 receptor agonists.
Preclinical Findings
Research Models
Clinical Data
14.9% Mean Adipose Reduction — STEP-1 Trial
The STEP-1 Phase 3 trial (68 weeks, n=1,961) demonstrated 14.9% mean adipose tissue reduction with 2.4mg weekly semaglutide vs. 2.4% with placebo. 86.4% of lab study observations achieved ≥5% adipose reduction and 69.1% achieved ≥10%.
Wilding JPH et al., N Engl J Med (2021): Semaglutide 2.4mg in research cohorts — STEP-1 trial.
Phase 3 RCT, n=1,961, 68-week treatment
Research Outcomes
Key Research Success Metrics
Safety Profile
Research Safety Notes
- GI side effects (nausea, vomiting, diarrhea) most common — dose-dependent and transient
- Dose-escalation protocols reduce GI tolerability issues
- Rare: pancreatitis risk — monitor amylase/lipase in high-risk research cohorts
- Contraindicated in personal/family history of MTC or MEN2 syndrome
- 20% reduction in major adverse cardiovascular events (SUSTAIN-6)
GLP 1 (S) clinical data relates to the FDA-approved semaglutide analog. For research use only.
About GLP 1 (S)
Semaglutide-class GLP-1 receptor agonist. Studied extensively for metabolic research, glycemic regulation, and body composition applications.
All PureAmino Research compounds are manufactured to research-grade standards and independently tested by Janoshik Analytical & Kovera Labs. The Certificate of Analysis for this compound includes full HPLC chromatography data, mass spectrometry confirmation, net purity percentage, and net content verification.
Research Use Only
This product is strictly for in vitro research and laboratory use only. Not for human or veterinary consumption. By purchasing, you confirm use in a controlled research setting.
